| Ytd | 89.42% | |
| 1y | 90.80% |
| Open | 7.96 | Prev Close | 7.86 | Low | 7.57 | High | 8.10 | Mkt Cap | 203.32M |
| Vol | 445.29K | Avg Vol | 349.21K | EPS | -2.17 | P/E | N/A | Forward P/E | -0.66 |
| Beta | 1.69 | Short Ratio | 2.42 | Inst. Own | 44.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 7.12 | 200-d Avg | 5.74 | 1yr Est | 33.60 |
Also in its updated corporate deck, the Company announced activation of a second clinical site at Wa
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its nove
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
Oppenheimer analyst Joseph Thome initiates coverage on Precision BioSciences (NASDAQ:DTIL) with a